Mallia Innovations develops products and therapies based on the immunomodulatory soluble CD83 (sCD83) protein, including cosmetic and clinical-stage programs. Its Mallia Aesthetics subsidiary markets the hormone-free 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum, which are based on the proprietary MAL-838 derivative and sold via the 8T3 website. Mallia Therapeutics focuses on clinical development of therapies such as MAL-856 for topical treatment of hair loss and other dermatological indications. The company emphasizes a multimodal, locally acting mode of action for sCD83 that promotes resolution of inflammation, activates regulatory T cells, protects follicular cells, and stimulates keratin production without systemic exposure. Following a successful launch in Germany and positive early sales, Mallia plans to scale marketing and sales across Europe, build inventory, and prepare for potential market entry outside the EU, particularly in the United States. The newly raised €3 million is intended to fund commercial expansion, operational strengthening, and regulatory and organizational preparations for international launches.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2026